Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission

Summary

RATIONALE: Vaccines made from a patient's white blood cells (dendritic cells) and a specific leukemia antigen (Wilms tumor antigen-1) may induce an effective immune response to kill residual leukemic cells and/or prevent leukemia relapse. PURPOSE: This phase I/II trial is studying the feasibility, safety and efficacy of intradermal mRNA-transfected dendritic cell vaccination therapy in patients with acute myeloid leukemia.

Timeline

Start

2005-03

Primary completion

2007-11

Completion

2008-12

Drugs

Indications